The molecular biology of chronic myeloid leukaemia

Leukemia

Volumn 10, Issue 5, 1996, Pages 751-756

  Melo, J V ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

BCR ABL; Chromosomal translocation; CML; PCR amplification

Indexed keywords

BCR ABL PROTEIN;

CENTROMERE; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; GENOME IMPRINTING; HEMATOPOIETIC STEM CELL; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 0029995607     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-291.
3. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New Engl J Med 1988; 319: 990-998.
4. BCR-ABL gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
5. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR-ABL. Proc Natl Acad Sci USA 1990; 87: 6649-6653.
6. Shepherd PCA, Ganesan TS, Galton DAG. Haematological classification of the chronic myeloid leukaemias. Baillière's Clin Haematol 1987; 1: 887-906.
7. Wiedemann LM et al. The correlation of breakpoint cluster region rearrangement and P210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases. Blood 1988; 71: 349-355.
8. Cogswell PC et al. Mutations of the Ras protooncogenes in chronic myelogenous leukemia: a high frequency of Ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989; 74: 2629-2633.
9. Selleri L et al. Chronic myelogenous leukemia with typical clinical and morphological features can be Philadelphia negative and 'bcr negative'. Hematol Pathol 1990; 4: 67-77.
10. Melo JV, Goldman JM. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia. Leukemia 1992; 6: 786-790.
11. Kurzrock R et al. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood 1990; 75: 445-452.
12. Hirsch-Ginsberg C et al. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia, Blood 1990; 76: 1214-1219.
13. Potter AM, Watmore A. Cytogenetics in myeloid leukaemia. In: Rooney DE, Czepulkowski BH (eds). Human Cytogenetics, vol. II. Oxford University Press: Oxford, 1992, pp 27-66.
14. Haas OA, Argyriou-Tirita A, Lion T. Parental origin of chromosomes involved in the translocation t(9;22). Nature 1992; 369: 414-416.
15. Feinberg AP. Genomic imprinting and gene activation in cancer. Nat Genet 1993; 4: 110-113.
16. Melo JV, Van X-H, Diamond J, Goldman JM. Lack of imprinting of the ABL gene. Nat Genet 1994; 8: 318-319.
17. Melo JV, Van X-H, Diamond J, Goldman JM. Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia. Leukemia 1995; 9: 734-739.
18. Fioretos T, Heisterkamp N, Groffen J. No evidence for genomic imprinting of the human BCR gene. Blood 1994; 83: 3441-3444.
19. Riggins GJ, Zhang F, Warren ST. Lack of imprinting of BCR. Nat Genet 1994; 6: 226.
20. Litz CE, Copenhaver CM. Paternal origin of the rearranged major breakpoint cluster region in chronic myeloid leukemia. Blood 1994; 83: 3445-3448.
21. Melo JV, Goldman JM. Are ABL and BCR imprinted? (Reply to Haas). Leukemia 1995; 9: 1407-1408.
22. Bentz M, Cabot G, Moos M, Speicher MR, Ganser A, Lichter P, Dohner H. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 1994; 83: 1922-1928.
23. Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 1985; 5: 3116-3123.
24. bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res 1987; 47: 1731-1739.
25. Lugo TG, Pendergaast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
26. Guo JQ, Wang JYG, Arlinghaus RB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res 1991; 51: 3048-3051.
27. 1-positive chronic myelogenous leukemia patients by an immunoblotting method. Leukemia 1993; 8: 1168-1173.
28. Bedi A et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 1993; 81: 2898-3001.
29. Cross NCP et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 6: 1929-1936.
30. van Rhee FV, Marks DI, Lin F, Szydlo RM, Hochhaus A, Treleaven J, Delord C, Cross NCP, Goldman JM, Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukaemia: comparison of blood and bone marrow. Leukemia 1995; 9: 329-335.
31. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood (in press).
32. Hochhaus A et al. Atypical BCR-ABL transcripts in chronic myelogenous leukemia (CML) patients detected by multiplex polymerase chain reaction. Blood 1995; 86 (Suppl. 1): 526a.
33. van der Plas DC et al. bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogenous leukemia patient. Leukemia 1991; 5: 457-461.
34. Iwata S, Mizutani S, Nakazawa S, Yata I. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia 1994; 8: 1696-1702.
35. BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8: 208-211.
36. Ito T et al. Induction of BCR-ABL fusion genes by in vitro X-irradiation. Jpn J Cancer Res 1993; 84: 105-109.
37. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 8: 3118-3122.
38. Diamond J, Goldman JM, Melo JV. BCR-ABL, ABL-BCR, BCR and ABL genes are all expressed in individual CFU-GM colonies derived from blood of patients with chronic myeloid leukemia. Blood 1995; 85: 2171-2175.
39. + cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 1994; 83: 1744-1747.
40. Zhang JC, Lin F, Chase A, Goldman JM, Cross NCP. Comparison of genomic DNA and cDNA for detection of disease after treatment of chronic myeloid leukemia by allogeneic bone marrow transplantation. Blood 1996 (in press).
41. Melo JV, Gordon E, Cross NCP, Goldman JM. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 1993; 81: 158-165.
42. rac. Nature 1991; 351: 400-402.
43. Ridley AJ et al. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992; 70: 401-410.
44. rac. Nature 1991; 353: 668-670.
45. Yin JL, Williams BG, Arthur CK, Ma DDF. Interferon response in chronic myeloid leukaemia correlates with ABL-BCR expression: a preliminary study. Br J Haematol 1995; 89: 539-545.
46. Melo JV, Hochhaus A, Van X-H, Godman JM. Lack of correlation between ABL-BCR expression and response to interferon-α in chronic myeloid leukaemia. Br J Haematol 1996; 92: 684-686.
47. Lisker R et al. Late appearing Ph chromosome in two patients with chronic myelogenous leukemia. Blood 1980; 56: 812-814.
48. Fialkow PJ et al. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58: 125-130.
49. Cannistra SA. Chronic myelogenous leukaemia as a model for the genetic basis of cancer. Hematol/Oncol Clin N Am 1990; 4: 337-353.
50. Ahuja H et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991; 87: 2042-2047.
51. Wetzler M, Talpaz M, Estrov Z, Kurzrock R. CML: mechanisms of initiation and progression. Leuk Lymphoma 1993; 11 (Suppl. 1): 47-50.
52. Feinstein E et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 1991: 88: 6293-6297.
53. Sawyers C. The role of MYC in transformation by BCR-ABL. Leuk Lymphoma 1993; 11 (Suppl. 1): 45-46.
54. Jennings B. A study of changes in methylation status and copy number at the c-myc locus during progression of chronic myeloid leukemia. Br J Haematol 1995; 89 (Suppl. 1): 37.
55. Ahuja HG, Jat PS, Foti A, Bar-Eli M, Cline MJ. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 1991; 78: 3259-3268.
56. Towatari M, Adachi K, Kato H, Saito H. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood 1991; 78: 2178-2181.
57. Sill H, Goldman JM, Cross NCP. Homozygous deletions of the p16 tumor suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995; 85: 2013-2016.
58. Mitani K et al. Generation of the AML1-EVI1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994; 13: 504-510.